The UK National Institute for Health Research has designated the PROTECT-V trial of Union Therapeutics’ UNI91103 niclosamide nasal spray for the treatment of COVID-19 in kidney patients as an Urgent Public Health (UPH) priority, the company said. Union announced the initiation of the PROTECT-V trial in February 2021.
Union co-founder Morten Sommer commented, “We are pleased that our COVID-19 program has achieved this important recognition through the UPH prioritization of the PROTECT-V study as it paves the way for a faster and more efficient conduct of the trial. The PROTECT-V trial is testing our product, a niclosamide-based nasal spray (UNI91103), in kidney patients, who may require additional protection from COVID-19 in addition to vaccination. Considering the medical needs within this high-risk patient group, it is vital that the trial will be able to roll out in an expeditated [sic] manner.”
Read the Union Therapeutics press release.
